US PTAB IP Litigation
8,722 annotated decisions
Page 324 of 364 · 8,722 total
patent instituted · Mar 27, 2024
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
· IPR2024-00733
Dyson successfully petitioned the PTAB to institute IPR proceedings against a patent covering cleaning apparatuses. The Board found reasonable likelihood of prevailing on grounds of anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
patent denied · Mar 27, 2024
AT&T Corp et al. v.Daingean Technologies Ltd.
· IPR2024-00730
The PTAB denied AT&T's IPR against Daingean Technologies, finding that the Petitioner failed to show a reasonable likelihood of success regarding claims related to code block segmentation and HARQ-ACKs. The denial hinged on insufficient support for the 'multiple CB/CBG limitation' in both cited prior art references.
patent denied · Mar 27, 2024
AT&T Corp et al. v.Daingean Technologies Ltd.
· IPR2024-00644
The PTAB denied institution of IPR against Daingean Technologies' patent, finding that the petitioner failed to prove its sole prior art reference (R2-1702708) was a publicly accessible printed publication.
patent · Mar 26, 2024
Ovid Therapeutics Inc. v.Marinus Pharmaceuticals, Inc.
· IPR2024-00726
Marinus Pharmaceuticals seeks to invalidate Ovid Therapeutics’ 2022 ganaxolone patent covering methods for treating status epilepticus, arguing anticipation, obviousness, and lack of enablement based on prior publications and press releases.
patent · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
Cisco and Fortinet seek a Director Review of a PTAB decision upholding InfoExpress’s network‑authentication patent. They contend the Board improperly allowed incorporation‑by‑reference arguments, violating USPTO rules and prejudicing the challengers. The petition asks the Director to vacate and remand the decision.
patent · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
InfoExpress defends its Network Access Control patent against Cisco and Fortinet’s Director Review request, asserting the Board correctly found no unpatentable claims. The petitioners’ new arguments are deemed untimely and forfeited.
patent all challenged claims upheld · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
Cisco and Fortinet successfully defended claims of InfoExpress’s network‑access control patent in IPR2024‑00677; the Board found no unpatentable subject matter.
patent denied · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
The USPTO Director denied Cisco’s request for review of the PTAB’s Final Written Decision in IPR2024-00677 and related cases. The order confirms that no Director Review will be granted.
patent · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
CISCO Systems requested Director Review in IPR2024-00677 concerning patent 8,578,444 owned by InfoExpress; the Board will decide whether to grant the review.
patent null · Mar 26, 2024
Ovid Therapeutics Inc. v.Marinus Pharmaceuticals, Inc.
· IPR2024-00726
Ovid Therapeutics challenges Marinus Pharmaceuticals' patent on ganaxolone, arguing that all claims are obvious over various combinations of clinical trial data and earlier patents. The petitioner asserts that prior art provides sufficient motivation for treating status epilepticus (SE) with the claimed dosing regimen.
patent null · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
CISCO SYSTEMS, INC. filed a Petition challenging 11 claims of InfoExpress Inc.'s patent (8578444) based on obviousness under 35 U.S.C. § 103. The petitioner argues that combining prior art references Krantz and Herrmann renders the claimed network access control features predictable to a POSITA.
patent denied · Mar 26, 2024
Ovid Therapeutics Inc. v.Marinus Pharmaceuticals, Inc.
· IPR2024-00726
Ovid Therapeutics Inc.'s IPR challenge against Marinus Pharmaceuticals, Inc. was denied by the PTAB on grounds of obviousness (103). The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing in its challenges regarding plasma concentration limitations and priority.
patent instituted · Mar 26, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00677
CISCO Systems and FORTINET successfully instituted an IPR against InfoExpress Inc.'s patent, finding a reasonable likelihood of obviousness over Krantz and Herrmann. The Board agreed that combining network authentication (Krantz) with policy enforcement (Herrmann) would teach the claimed method for auditing devices.
patent terminated or settled · Mar 25, 2024
MediaTek Inc. et al. v.MOSAID Technologies Inc.:
· IPR2024-00719
MediaTek and MOSAID settled their dispute over U.S. Patent 7,945,885, leading to the joint termination of four inter partes review proceedings. The Board granted confidentiality treatment for the settlement agreement while denying its separation from the IPR files.
patent terminated or settled · Mar 25, 2024
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
· IPR2024-00713
Intersect ENT and New Amsterdam, LLC have entered a settlement that resolves all disputes over U.S. Patent 6,916,483. They jointly moved to terminate the inter partes review, citing the settlement and lack of further contest.
patent terminated or settled · Mar 25, 2024
MediaTek Inc. et al. v.MOSAID Technologies Inc.:
· IPR2024-00719
MediaTek and MOSAID have settled their dispute over U.S. Patent No. 7,945,885 and jointly filed a motion to terminate the pending inter partes review. The Board is asked to dismiss the proceeding under 35 U.S.C. §317.
patent · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00706
Vicor Corporation requests Director Review of PTAB’s denial to institute an IPR against Delta Electronics’ 10,877,534 patent covering stacked power converters. The petition argues the Board improperly relied on expert testimony about heat‑dissipation without objective evidence, contrary to prior art.
patent denied · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00706
The USPTO denied Vicor Corporation’s request for Director Review of the institution decisions in IPR2024-00706, leaving the denial of institution intact.
patent · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00715
Vicor Corporation has filed a Director Review request challenging the Board’s denial to institute an IPR on Delta Electronics’ 10,877,534 patent covering stacked power converters. The petitioner contends the Board relied on unsupported expert testimony contrary to prior art.
patent · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00715
Vicor Corporation filed a Director Review request after the USPTO denied its institution petition in IPR2024-00715, arguing the Board should have considered the patent owner's expert testimony despite lacking documentary support.
patent terminated or settled · Mar 25, 2024
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
· IPR2024-00713
Intersect ENT and New Amsterdam settled their IPR dispute over U.S. Patent 6,916,483, filing a joint motion that led the PTAB to terminate the proceeding before trial.
patent · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00704
Vicor Corporation filed a Request for Director Review after the PTAB refused to institute an IPR against Delta Electronics’ power‑converter patent. The petition argues that petitioners should be allowed to rely on the patent owner’s infringement claim constructions, even if they disagree with them, citing a split among PTAB panels.
patent denied · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00704
The USPTO denied Vicor Corporation's request for Director Review of the decision denying institution of IPR2024-00704 concerning Delta Electronics' patent 8,711,580. No further substantive rulings on claim patentability were made.
patent · Mar 25, 2024
Vicor Corporation v.Delta Electronics, Inc.
· IPR2024-00704
Vicor seeks Director Review after the PTAB denied institution of its IPR, contending the denial was improper because it hinged on the patent owner’s claim construction.
